2015 American Society of Clinical Oncology Annual Meeting*

May 29-June 2, 2015; Chicago, Illinois
Naiyer Rizvi, MD, and Heather Wakelee, MD, review data from key lung cancer presentations from the 2015 clinical oncology meeting in Chicago.
person default
Naiyer Rizvi, MD
person default
Heather Wakelee, MD

Lung Cancer

Results of phase II/III trial suggest that Bevacizumab/Pemetrexed/Cisplatin is a new treatment option although increased toxicity is a potential concern

Released: June 2, 2015

In this phase Ib study, pembrolizumab demonstrated promising antitumor activity in SCLC with a 35% overall response rate and 25% of patients experiencing a partial response.

Released: June 1, 2015

Results of phase I study of nivolumab with or without ipilimumab in patients with SCLC and progression on prior therapy.

Released: May 31, 2015

AZD9291, a third-generation irreversible EGFR tyrosine kinase inhibitor, demonstrated an ORR of 73% with few grade ≥ 3 adverse events in previously untreated patients with EGFR mutation–positive, advanced NSCLC.

Released: June 1, 2015

Rociletinib, a third-generation EGFR TKI, is active in patients with acquired resistance to previous EGFR TKI therapy as detected by either standard tumor tissue biopsy or a plasma-based assay.

Released: June 2, 2015

Phase II study results suggest dabrafenib plus trametinib have meaningful antitumor activity, manageable safety profile in BRAF V600E–mutated NSCLC.

Released: June 3, 2015

Results from the CheckMate 017 trial, which led to FDA approval of nivolumab in advanced squamous NSCLC, show 3.2 month improvement in overall survival with fewer adverse events vs docetaxel.

Released: June 1, 2015

In an interim analysis of atezolizumab as second-line or third-line therapy for advanced NSCLC, clinical efficacy correlated with PD-L1 expression level.

Released: June 2, 2015

Early results from this phase I trial indicate a manageable safety profile along with robust, durable activity with pembrolizumab + ipilimumab in previously treated patients with advanced NSCLC.

Released: June 2, 2015

Results from the CheckMate 057 trial demonstrate superior OS and favorable safety profile with nivolumab vs docetaxel in patients with advanced nonsquamous NSCLC who failed prior platinum-based doublet chemotherapy.

Released: May 31, 2015

Naiyer Rizvi, MD, and Heather Wakelee, MD, provide their analysis of key lung cancer presentations from the 2015 clinical oncology meeting in Chicago.

person default Naiyer Rizvi, MD person default Heather Wakelee, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Released: August 7, 2015 Expiration: August 6, 2016

In this downloadable slideset of lung cancer clinical trial highlights from the 2015 American Society of Clinical Oncology annual meeting, Naiyer Rizvi, MD, and Heather Wakelee, MD, discuss key immunotherapy studies in NSCLC and SCLC, review targeting of driver mutations, and discuss treatment of mesothelioma.

Released: August 7, 2015
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Educational grant provided by:
AstraZeneca
Bayer Healthcare Pharmaceuticals Inc.
Bristol-Myers Squibb
Celgene Corporation
Genentech BioOncology
Incyte
Novartis Pharmaceuticals Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?